Form PTO-1449	TIC	N DISCLOSUDE COM	Doc	ket Number (Optional)		Application Number	Sneet Page 1 014	
INFORMATION DISCLOSUBE OF THE TION IN AN APPLICATION				HMV-038.02 Applicant		09/538,106		
(0	Jse se	everal sheets iffnecessary)	% Mc	Keon et al.				
SEP 1 7 2004 1			2004 3 rin	Filing Date Group Art Unit March 29, 2000 1642				
				S. PATENT DOCUME	NTS			
EXAMINER INITIAL		DOCUMENT NORTH	DATE	NAME	CLAS	S SUBCLASS	FILING DATE IF APPROPRIATE	
•	\downarrow			·				
	-							
	-							
	+							
	<u> </u>		FOR	EIGN PATENT DOCUM	1ENTS			
	1	DOCUMENT NUMBER	DATE	COUNTRY CL	CLASS	SUBCLASS	Translation YES NO	
	\downarrow							
	-							
	-							
	<u> </u>	ОТН	ER DOCUM	IENTS	(1 - 1 - 1) -			
CY	BV	Baylin et al., "KILLE		DNA damage-inducible p53-r	egulated death rec	tuthor, Title, Date, Per eptor gene," Natur	e Genetics,	
	BW	Beaudry et al., "Therapeutic targeting of the p53 tumor suppressor gene," Pharmaceutical Biotechnology, 592-600						
	вх	Cviko et al., "Adenoid basal carcinomas of the cervix: a unique morphological evolution with cell cycle correlates," Hum Pathol., 31(6):740-744 (2000)						
	BY	Damiani et al., "Myoepithelial cells and basal lamina in poorly differentiated in situ duct carcinoma of the breast," Virchows Arch, 434:27-234 (1999)						
	ВZ	De Laurenzi et al., "Evolution of Functions within the p53/p63/p73 Family," Ann N Y Acad Sci., 926:90-100 (2000)						
	CA	Foschini et al., "Carcinomas of the breast showing myoepithelial cell differentiation," Virchows Arch, 432:303-310 (1998)						
CY	СВ	Friedman et al., "The 90:3319-3323 (1993)	p53 protein is	s an unusually shaped tetrame	er that binds direct	ly to DNA," Proc.	Natl. Acad. Sci.,	
EXAMINER		<u> </u>		DATE	CONSIDERED			
EVAMINED	la de	Chrispi	12_		12	6/04		
SAAMINEK: Sonformance a	Initia nd no	at it citation considered, vot considered. Include co	vhether or not o py of this form	itation is in conformance with M with next communication to the	1PEP § 609; Draw applicant.	ine through citation	if not in	
					- •			

Form PTO-1449			D-1-11-1-10-1			Sheet Page 2 of 4	
INFORMA	TIO	N DISCHOSURE CITYENON	Docket Number (Optional) HMV-038.02		Application Number 09/538,106		
IN AN APPLICATION			Applicant	<u></u>	09/336,100		
"	lse se	veral sheets if necessary)	McKeon et al.				
1		SEP 1 7 2004	Filing Date March 29, 2000		Group Art Unit		
		В ОТНЕЙ DO		(In aludina	1642	ant Proces Co. 1	
	T	Huibregie et al cellular		on of n53 with the E6 on	Author, Title, Date, Pertin	eni Pages Elc.)	
	lcc	types 16 or 18," The EMBO.	Journal, 10(13):4129-4135	(1991)	coprotein of numan pa	pinomavirus	
CY	-	1	, .(,.	()			
	Huibregtse et al., "Cloning and Expression of the cDNA for E6-AP, a Protein that Mediates the Interaction of the						
•	CD	Human Papillomavirus E6 Or	acoprotein with p53." Mole	cular and Cellular Biolo	ngv. 13(2):775-784 (19	993)	
} (CD Human Papillomavirus E6 Oncoprotein with p53," Molecular and Cellular Biology, 13(2):775-784 (1993)						
	Ince et al., "p63 Coordinates Anogenital Modeling and Epithelial Cell Differentiation in the Developing Female						
	CE	Urogenital Tract," Am Journa	of Pathol., 161(4):1111-1	117 (2002)	unon in the Developh	ig i chimic	
1 1		27 27 27 27 27 27 27 27 27 27 27 27 27 2					
	T	Lazar et al., "Transforming G	rowth Factor a: Mutation	of Aspartic Acid 47 and	Leucine 48 Deculte in	Different	
	CF	Biological Activities," Molec	ular and Cellular Biology.	8(3):1247-1252 (1988)	Leucine 40 Results in	Different	
1			6,7	-(-)			
	1	Le Bras et al., "Monoclonal a	ntibodies raised against Xe	nopus p53 interact with	human n73 " Oncoge	ne 21·1304	
1	CG	1308 (2002)		mopeo poo mitorate with		10, 21.1504-	
1							
	Т	Levero et al., "The p53/p63/p	73 family of transcription f	actors: overlapping and	distinct functions." I	Cell Sci	
	СН	113:1661-1670 (2000)	•			oon bot.	
_	L						
	Γ	Lohrum et al., "Regulation an	d function of the p53-relate	ed proteins: same family	different rules." Tren	ds Cell Biol	
j	CI	10(5):197-202 (2000)		- p	, american ruics, Trea	ids Cell Biol.,	
	1						
		Mills et al., "p63 is a p53 hom	ologue required for limb a	nd epidermal morphogei	nesis "Nature 398-70	8-713 (1999)	
j	C1	•		or of an area and broad a		0 / 15 (1777)	
	<u> </u>					ļ	
		Nayar et al., "Immunoreactivit	ty of ductal cells with putat	ive myoepithelial marke	ers: a potential pitfall i	n breast	
ĺ	CK	carcinoma," Ann Diagn Patho	1., 3:165-173 (1999)	•	•		
İ	1	O'Connell et al., "Identification of a Basal/Reserve Cell Immunophenotype in Benign and Neoplastic Endometrium:					
	CL	A Study with the p53 Homologue p63," Gynecol Oncol., 80(1):30-36 (2001)					
	Osada et al., "Cloning and functional analysis of human p51, which structurally and functionally resembles p53," Nat					bles p53," Nat	
ı	СМ	Med., 4(7):839-843 (1998)					
j		Quade et al., "Expression of th	e p53 Homologue p63 in E	arly Cervical Neoplasia	," Gynecol Oncol, 80	(1):24-29	
	CN	(2001)					
	\sqcup						
		Ramnani et al., "Basal Cell-Sp	ecific Anti-Keratin Antibo	dy 34βE12: Optimizing	Its Use in Distinguish	ing Benign	
	CO	Prostate and Cancer," Mod. Pa	tnology, 12:443-444 (1999	")		Ī	
	\vdash	Salamata et al. 40 '5					
1	СР	Sakamoto et al., "Specific sequ tetramers in solution," Proc. Na	iences from the carboxyl te	rminus of human p53 ge	ene product form anti-	parallel	
1		cuamers in Solution, Proc. N	au. Acau. 301., 9:89/4-89/	0 (1994)		ļ	
	 	Scheffner et al "Internation of	Fthe Human Danillana	- T 16 EC O			
Scheffner et al., "Interaction of the Human Papillomavirus Type 16 E6 Oncoprotein with Wild-Type and Human p53 Proteins," Journal of Virology, 66(8):5100-5105 (1992)				d Mutant			
CY	CY CQ Human p35 Flotents, Journal of Virology, 66(8):5100-5105 (1992)						
EXAMINER	EXAMINER DATE CONSIDERED						
	Chrosp H X 12/6/04						
EXAMINER:	Initia	if citation considered, whether or	not citation is in conformance	with MPEP § 609; Draw		ot in	
conformance as	nd no	t considered. Include copy of this	form with next communication	n to the applicant.			
				•		{	

INFORMATION DISCLOSURE CHATION			Docket Number (Optional)		Application Number	
IN AN APPLICATION			HMV-038.02 Applicant		09/538,106	
(Us	se se	veral sheets if necessary)	McKeon et al.			
SEP 1 7 2004 1			Filing Date March 29, 2000		Group Art Unit 1642	
	_	OTHER 900		(Including	Author, Title, Date, Pertinent Pages Etc.)	
	CR	Scheffnetet al., "The PPV-10 of p53," Cell, 75.495-505 (19	6E6 and E6-AP Complex Fi	unctions as a Ubiquitin-	Protein Ligase in the Ubiquitination	
LY		01 p35, Con, 75.495-305 (19	,			
-		Schweizer et al., "A reversibl	y palmitovlated resident pro	tein (p63) of an ER-Go	olgi intermediate compartment is	
	CS	Schweizer et al., "A reversibly palmitoylated resident protein (p63) of an ER-Golgi intermediate compartment is related to a circulatory shock resuscitation protein," Journal of Cell Science, 4:685-694 (1993)				
	СТ	Senoo et al., "A Second p53-Related Protein, p73L, with High Homology to p73," Biochem Biophys Res Commun., 248(3):603-607 (1998)				
	си	Signoretti et al., "Basal Cell Specific p63 is Useful in the Differential Diagnosis of benign vs. Malignant Lesions of the Prostate," Presentation at the United States and Canadian Academy of Pathology (USCAP), March 29, 2000				
	cv	Signoretti et al., "p63 Is a Prostate Basal Cell Marker and is Required for Prostate Development," Am Journal of Pathol., 157(6):1769-1775 (2000)				
	cw	Sternlicht et al., "The Human Myoepithelial Cell Is a Natural Tumor Suppressor," Clin Cancer Research, 3:1949-1958 (1997)				
	сх	Theis et al., "A function in apoptosis other than transactivation inherent in the NH ₂ -terminal domain of p53," International Journal of Cancer, 71:858-866 (1997)				
	CY	Totten et al., "Microscopic Differential Diagnosis of Latent Carcinoma of Prostate," Arch Pathol., 55:131-141 (1953)				
	cz	Trink et al., "A new human p53 homologue," Nat. Med. 4(7):747-748 (1998)				
	DA	Urist et al., "Loss of p63 Expression is Associated with Tumor Progression in Bladder Cancer," Am Journal of Pathol., 161(4):1199-1206 (2002)				
	DB	Varma et al., "Discriminant staining patterns of small glandular and preneoplastic lesions of the prostate using high molecular weight cytokeratin (HMCK) - A study of 301 consecutive needle biopsies," Abstract, Mod Pathol., 1997, 10:93A				
	DC	Varma et al., "Effect of Formalin Fixation and Epitope Retrieval Techniques on Antibody 34βE12 Immunostaining of Prostatic Tissues," Mod Pathol., 12:472 (1999)				
1	DD	Wang et al., "Histologic and Immunophenotypic Classification of Cervical Carcinomas by Expression of the p53 Homologue p63: A Study of 250 Cases," Hum Pathol., 32(5):479-486 (2001)				
	DE	Yang et al., "Lineage-specific expression of the P53 homologue P63 in genital tract neoplasia," Abstract, Mod Pathol., January 1999, 127A				
<γ	DF	Yang et al., "P63: a P53 homol Abstract, Mod Pathol., January	ogue that is a differentiation 1999, 178A	n-specific marker in cer	vical squamous epithelium,"	
EXAMINER	(Chruss H'	2	DATE CONSIDERED	2/6/04	
EXAMINER: In conformance and	nitia d not	if citation considered, whether or a considered. Include copy of this f	not citation is in conformance form with next communication	with MPEP § 609: Draw	line through citation if not in	

Form PTO-1449			T	Sheet Page 4 of 4
INFORMA	TIO	DISCOSURE CIPATION	Docket Number (Optional) HMV-038.02	Application Number 09/538,106
IN AN APPLICATION 6			Applicant	
SEP 1 7 2004			McKeon et al. Filing Date	Group Art Unit
			March 29, 2000	1642
		OTHER DOCUME	NTS (Including Author, Title, Date, Pertine	
		Yang et al. Pare Expression J Surg Pathol., 23(2):147-152	n of High-Molecular-Weight Cytokeratin in Adend	ocarcinoma of the Prostate Gland," Am
CY	DG	J Surg Fautor., 23(2):147-132	2 (1999)	
		Zeng et al., "NBP is the p53	homolog p63," Carcinogenesis, 22(2):215-219 (20	001)
CY	DН	0 , ====per	215 (20	
	li			
	+			
	\vdash			
	li			
	\vdash			
	\vdash			
				
	+			
				ļ
	$-\downarrow$			
EXAMINER		$\overline{\Omega}$	DATE CONSIDERED	
	(Throp,	· I	le loss
EXAMINER:	Initial	if citation considered, whether or	not citation is in conformance with MPEP § 609: Dray	v line through citation if not in
conformance an	d not	considered. Include copy of this	form with next communication to the applicant.	